On August 11, 2025, WW International announced its second quarter fiscal 2025 results, the first post-bankruptcy, confirming the successful completion of its strategic reorganization and a $1.15 billion debt reduction. Due to fresh start accounting, Q2 2025 results were presented with a 'Predecessor' period (March 30 - June 24) and a 'Successor' period (June 25 - June 30).
Combined revenues for Q2 were $189 million, a 6% decrease year-over-year, with combined end-of-period subscribers at 3.2 million. However, the Clinical segment continued its growth trajectory, with combined end-of-period clinical subscribers increasing 56.5% year-over-year to 127 thousand, generating $31 million in combined clinical revenues, up 55% year-over-year. The Predecessor period reported a net income of $1,191 million, significantly impacted by reorganization items, while the Successor period showed a net income of $1 million.
WeightWatchers also confirmed a strategic shift, stating it is now only offering Wegovy, shunning compounded semaglutide amid FDA rules. This decision is expected to create near-term headwinds for clinical subscriber growth as members transition to higher-priced FDA-approved alternatives. The company reiterated its full-year fiscal 2025 guidance for total combined revenues of $685 million to $700 million and Adjusted EBITDA of $140 million to $150 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.